Introduction
============

Insulin is increasingly used in the treatment of type 2 diabetes (T2D), with its usage reaching 30--50% in Western countries ([@b1-etm-0-0-3117]). Nevertheless, many patients receiving insulin therapy develop vascular diseases, such as coronary heart disease and stroke ([@b2-etm-0-0-3117]). Therefore, the role of insulin in the development of atherosclerosis (AS) is controversial. Previous findings have shown that increased physiological doses of insulin promote vascular endothelial injury, as well as vascular smooth muscle cell proliferation and migration, thereby contributing to the process of AS ([@b3-etm-0-0-3117]--[@b5-etm-0-0-3117]). By contrast, it has been reported that insulin delays the process of AS by upregulating nitric oxide synthetase which enhances vasorelaxant function of vascular endothelial cells ([@b6-etm-0-0-3117]). However, previous studies have not focused on the association between insulin dosage (ID) and usage time, and the coronary artery lesions in patients of T2D and coronary heart disease.

The aim of this study was to examine the association between insulin usage (both dose and time) and coronary artery lesions in these patients. Thhe results showed that high doses of insulin or a high IT/DT ratio may aggravate coronary artery damage.

Materials and methods
=====================

### Patients

A total of 353 patients with T2D were recruited in the Department of Cardiology, Daping Hospital, The Third Military School (Chonqing, China). All the patients signed an informed consent prior to participating in the present study. The study protocol was approved by the Human Ethics Committee of Daping Hospital.

The inclusion criteria for the present study included, 35--85 years of age and a previous history of T2D, or patients meeting the diagnostic criteria of the '2013 Guidelines for the Prevention and Treatment of Diabetes in China' ([@b7-etm-0-0-3117]), as well as having undergone coronary arteriography, and ongoing insulin therapy. Exclusion criteria for the study were liver or, kidney disease, anemia \[defined as hemoglobin (Hb) of \<60 g/l\], tumor or severe malnutrition. Patients were also excluded if they were using glucagon-like peptide-1 receptor agonists, rosiglitazone, dipeptidyl peptidase-4 inhibitors, or α-glucosidase inhibitors within 3 months of screening.

The patients were divided into the high-dose (≥0.5 IU/kg) and low-dose (\<0.5 IU/kg) groups based on insulin usage dosage ([@b8-etm-0-0-3117]).

### Patient information

Patient information such as age, gender, smoking, measured height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), ID, insulin usage time (IT), diabetes duration time (DT), caculated body mass index (BMI) and the IT/DT ratio were collected.

### Biochemical analysis

After 12 h of fasting, 3 ml of fasting venous blood was collected in the morning of the second day after hospitalization. Low-density lipoproteincholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), total cholesterol (TC), triglycerides (TG), fasting blood glucose (Glu), HbA1c, and C-peptide were quantified using automatic biochemical analyzers (Model Beckman DxC800; Beckman Coulter, CA, USA) and the Cobas 8000 (Model Roche Diagnostics, Roche, IN, USA).

### Calculation of Gensini score

The Gensini score was calculated by assigning a severity score on each coronary stenosis, based on the degree of luminal narrowing and geographic importance. Reduction in the lumen diameter, and the radiologic appearance of concentric lesions and eccentric plaques were assessed. Reductions of 25, 50, 75, 90 and 99%, and complete occlusion were allocated a Gensini score of 1, 2, 4, 8, 16 and 32. Involvement of each principal vascular segment was assigned a multiplier defined by the functional significance of the myocardial area supplied by that segment. Thus, the left main coronary artery received a multiplier ×5, proximal segment of the left anterior descending coronary artery −×2.5, proximal segment of the circum flex artery −×2.5, mid-segment of the left anterior descending coronary artery −×1.5, while right coronary artery, distal segment of the left anterior descending coronary artery, posterolateral artery, and obtuse marginal artery received a multiplier ×1. The sum of the adjusted results made the total Gensini score.

### Statistical analysis

Data were analyzed using SPSS 18.0 software (SPSS, Chongqing, China). Data were presented as the mean ± standard deviation. Due to large individual differences of fasting insulin (FINS) levels and coronary Gensini scores, the data were analyzed following a logarithm transition.

A one-way analysis of variance was utilized when the variance was homogeneity. A non-parametric test was used for parameters when the variance was heteroscedasticity. The homeostasis model assessment-insulin sensitivity (HOMA-IS) index was assessed by HOMA2. Based on the HOMA-insulin resistance (IR) (50%), the patients were classified into insulin-sensitive and -insensitive individuals. Analysis between ID, IT, DT, and IT/DT correlations with the coronary artery damage Gensini score was determined, where the correlative degree was expressed by the correlation coefficient (r). Multivariate regression analysis among ID, IT, DT, and IT/DT was performed to determine the correlations with the coronary artery damage Gensini score. ID, IT, DT, and IT/DT were compared between the subgroups, according to the interquartile range (IQR) method (Q1, Q2, Q3 and Q4). The ID, IT, DT, and IT/DT values of patients with coronary artery disease (Gensini score \>0) were analyzed with receiver operating characteristic (ROC) curves. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Patient data and outcomes were compared between the high- and low-dose groups ([Table I](#tI-etm-0-0-3117){ref-type="table"}). Statistically significant differences were observed between the two groups for the levels of insulin C-peptide, HbA1c, ID, IT, DT, the IT/DT ratio and Gensini\'s score values (P\<0.05, the high- vs. low-dose groups). No significant differences were observed regarding patients\' gender, smoking history, age, BMI, the levels of TC, TG, LDL, HDL, FINS levels, Glu, or SBP or DBP (P\<0.05) ([Table I](#tI-etm-0-0-3117){ref-type="table"}).

Based on the HOMA-IR (50%), the patients were classified as insulin-sensitive (n=173) and -insensitive (n=180) ([Table II](#tII-etm-0-0-3117){ref-type="table"}). The Gensini score in insulin-insensitive patients was significantly greater than that in insulin-sensitive patients (P\<0.05) ([Table II](#tII-etm-0-0-3117){ref-type="table"}).

In addition, ID, IT, DT, and the IT/DT ratio positively correlated with the Gensini score (P\<0.05) ([Table III](#tIII-etm-0-0-3117){ref-type="table"}).

The multivariate regression analysis revealed which factors were associated with changes in ID (OR = 0.230, P\<0.01) and the IT/DT ratio (OR = 0.300, P\<0.01) ([Table IV](#tIV-etm-0-0-3117){ref-type="table"}).

Based on the IQR method, indices such as ID (≤20, 20--30, 30--40, ≥40), IT (≤1, 1--3, 3--6, ≥6), DT (≤5, 5--10, 10--14, ≥14), and the IT/DT ratio (≤0.3, 0.3--0.4, 0.4--0.6, ≥0.6), were compared between subgroups (Q1, Q2, Q3 and Q4) ([Table V](#tV-etm-0-0-3117){ref-type="table"}).

Statistics showed that the coronary artery damage Gensini score of the highest indicator subgroup (Q4) was significantly higher than that in the lowest indicator subgroup (Q1). In addition to IT, there were also significant differences between the remainig three indices of the subgroups ([Fig. 1](#f1-etm-0-0-3117){ref-type="fig"}).

We carried out a ROC curve analysis on ID, IT, DT, and the IT/DT ratio. ROC analysis revealed that the ID area under the ROC curve was 0.820 (range, 0.696--0.945), the IT/DT area under the ROC curve was 0.733 (range, 0.599--0.867), and IT area under the ROC curve was 0.708 (range, 0.552--0.864). These indices were statistically significant ([Table VI](#tVI-etm-0-0-3117){ref-type="table"}). However, the DT ROC curve did not obtain statistical significance ([Fig. 2](#f2-etm-0-0-3117){ref-type="fig"}).

Discussion
==========

At present, insulin is used early to control blood Glu of patients with T2D ([@b9-etm-0-0-3117]--[@b10-etm-0-0-3117]). Excessive use of insulin is common in China ([@b11-etm-0-0-3117]). However, such excessive use of insulin potentially leads to hypoglycemia, insulin resistance and even hyperinsulinemia ([@b2-etm-0-0-3117]). Thus, the effect insulin has on the occurrence and development of AS remains controversial. It has been shown that high doses of insulin reduce plasma levels of interleukin-6, interleukin-8, and tumor necrosis factor-α, thereby attenuating inflammatory processes, promoting heart metabolism, and facilitating the recovery of myocardial cells and its myocardial functions ([@b12-etm-0-0-3117]--[@b15-etm-0-0-3117]). However, high doses of FINS (ID) aggravate the severity of coronary artery disease ([@b3-etm-0-0-3117],[@b4-etm-0-0-3117]). In addition, no studies have been conducted thus far with regard to the association between IT, DT and coronary AS. Therefore, IT and DT were included in the present study. We observed a positive association between IT, DT and Gensini scores. In order to show the extent of early treatment of insulin, the concept of 'insulin usage time/diabetes duration time (IT/DT)' was applied in the study, for the first time, to the best of our knowledge. A positive association between IT/DT and Gensini score was also identified. The ROC analysis clearly revealed that ID, IT, IT/DT were predictive of the severity of coronary artery damage

Long-term administration of exogenous insulin can lead to lipid abnormality and vascular wall thickening ([@b4-etm-0-0-3117],[@b16-etm-0-0-3117]). In animals, insulin induces experimental AS ([@b4-etm-0-0-3117]). Coronary heart disease and AS induced by high-dose insulin may be due to: i) stimulation of proliferation and migration of arterial smooth muscle cells ([@b17-etm-0-0-3117]), ii) stimulation of uptake of cholesterol and LDL-C by endothelial cells of capillary vessels, which causes a combination of LDLs with arterial smooth muscle cells and mononuclear macrophage ([@b18-etm-0-0-3117]--[@b21-etm-0-0-3117]), iii) release of platelet-derived growth factor, insulin-like growth factor-1 and other inflammatory factors, by activating insulin mitogen-activated protein kinase/phosphoinositide 3-kinase signal transduction pathways using high-dose insulin. Combined, this inhibits release of nitric oxide, causing endothelial cell damage and oxidative stress, and leading to AS ([@b22-etm-0-0-3117]--[@b24-etm-0-0-3117]). Thus, hyperinsulinemia may be a risk factor of coronary heart disease and AS ([@b25-etm-0-0-3117]--[@b27-etm-0-0-3117]). Our finding showed statistical differences between the high-dose group (≥0.5 IU/kg) and low-dose group (\<0.5 IU/kg), such as insulin C-peptide, HbA1c, ID, DT, IT, IT/DT and the Gensini\'s score values (P\<0.05). The correlation analysis revealed the ID, IT, DT and IT/DT values were positively correlated with the coronary artery damage Gensini score. These data suggest that the degree of the coronary artery lesions were correlated with insulin doses or insulin usage time.

In the present study, insulin-insensitive patients had significantly higher Gensini scores. Based on this, we suggest that for T2D patients who do not take lifestyle intervention on diet, physical activity and smoking-insulin sensitivity should be calculated based on blood Glu and FINS levels when selecting the insulin-sensitizing treatment. If the effect is not satisfactory, exogenous insulin therapy should be administered based on weight to avoid overdosing. If recovery of the islet cell sensitivity to Glu, tested by HOMA, in T2D patients after insulin use occurs, the treatment plan should be adjusted to avoid long-term excessive exposure to insulin and minimize the damage of insulin to blood vessels.

In conclusion, the results of the present study suggest that in T2D patients in, higher ID or the ratio IT/DT are associated with more serious coronary injury. This finding suggests that an early and longer-term administration of high-dose of insulin may negatively impact coronary vessels.
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###### 

Comparison of patients\' demographic and biochemical characteristics between low- and high-dose insulin groups.

  Parameters             Low-dose insulin   High-dose insulin   P-value
  ---------------------- ------------------ ------------------- ---------
  Gender (male/female)   179 (105/74)       174 (92/82)         0.099
  Age, years             64.91±9.59         66.62±8.85          NS
  Smoking history        76                 84                  NS
  BMI, kg/m^2^           25.34±3.22         25.08±3.21          NS
  LDL-C, mmol/l          2.46±0.79          2.69±0.78           0.063
  HDL-C, mmol/l          1.10±0.30          1.04±0.31           NS
  TC, mmol/l             4.43±1.13          4.75±1.26           NS
  TG, mmol/l             1.79±1.36          1.92±1.48           NS
  Insulin, pmol/l        1.91±0.55          1.88±0.50           NS
  Glu, mmol/l            8.54±3.91          9.12±3.36           NS
  HbA1c, mmol/l          7.92±1.97          8.75±2.09           0.013
  C-peptide, mmol/l      2.86±1.90          2.27±1.75           0.048
  SBP, mmHg              146.52±25.83       152.15±28.48        NS
  DBP, mmHg              82.30±14.35        81.92±13.74         NS
  Insulin dose, IU       20.37±7.08         38.74±8.98          \<0.001
  DT, years              8.24±5.05          13.27±8.19          \<0.001
  IT, years              3.05±2.62          6.50±5.42           \<0.001
  Ratio of IT/DT         0.41±0.27          0.49±0.19           0.034
  Gensini score          30.82±30.07        48.20±36.76         0.002

BMI, body mass index; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglyceride; Glu, glucose; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; DBP, diastolic blood pressure; DT, diabetes duration time; IT, insulin usage time; NS, not significant. Data are presented as absolute numbers or as the mean ± standard deviation.

###### 

Insulin-sensitivity vs. coronary artery damage.

  Parameter       Insulin-insensitive patients, n=173   Insulin-sensitive patients, n=180   P-value
  --------------- ------------------------------------- ----------------------------------- ---------
  Gensini score   45.08±37.79                           33.89±30.31                         0.044

Data are presented as mean ± standard deviation.

###### 

Correlation between insulin dose, IT, DT, the IT/DT ratio, and Gensini score.

  Parameter       Insulin dose   IT           DT          Ratio of IT/DT
  --------------- -------------- ------------ ----------- ----------------
  Gensini score   r=0.300        r=0.319      r=0.163     r=0.281
  P-value         (P\<0.001)     (P\<0.001)   (P=0.044)   (P\<0.001)

DT, diabetes duration time; IT, insulin usage time.

###### 

Multivariate regression analysis of association between insulin dose, IT, DT, the IT/DT ratio, and Gensini score.

  Parameters   Insulin dose   IT      DT      Ratio of IT/DT
  ------------ -------------- ------- ------- ----------------
  Odds ratio   0.230          0.142   0.214   0.300
  P-value      0.007          0.410   0.166   0.009

DT, diabetes duration time; IT, insulin usage time.

###### 

Analysis of insulin dose, IT, DT, and the IT/DT ratio in subgroups by the interquartile range method.

  Parameters       Q1      Q2         Q3         Q4
  ---------------- ------- ---------- ---------- -------
  Insulin dose     \<20    20--30     30--40     \>40
  IT               ≤1      1--3       3--6       ≥6
  DT               ≤5      5--10      10--14     ≥14
  Ratio of IT/DT   \<0.3   0.3--0.4   0.4--0.6   \>0.6

DT, diabetes duration time; IT, insulin usage time.

###### 

Analysis of insulin dose, IT, DT, and the IT/DT ratio in subgroups by ROC method.

  Parameters       Area    P-value   Lower limit   Upper limit
  ---------------- ------- --------- ------------- -------------
  Insulin dose     0.820   0.001     0.696         0.945
  IT               0.708   0.028     0.552         0.864
  DT               0.637   0.149     0.552         0.864
  Ratio of IT/DT   0.733   0.014     0.599         0.867

ROC, receiver operating characteristic; DT, diabetes duration time; IT, insulin usage time.
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